Exceeded EBITDA Expectations
Adjusted EBITDA of $87 million exceeded expectations, driven by positive outcomes in pricing, collections, and expense controls.
Strong Year-to-Date Performance
2025 year-to-date results have been strong with no expectation of deviations from normal seasonality in the fourth quarter.
Share Buyback Achievement
Pediatrix bought back 1.2 million shares during the quarter, with a total of 1.7 million shares bought back to date.
Strong Same-Unit Growth
Same-unit growth of 8% with pricing up 7.5% and patient service volumes up 40 basis points.
Increased Operating Cash Flow
Generated $138 million in operating cash flow, up from $96 million in the prior year.
Innovative Technology Implementation
Introduction of proprietary system BabySteps, enhancing clinical outcomes for NICU patients.
Research Leadership
Pediatrix's clinicians authored 1,395 peer-reviewed publications, with substantial clinical research activity.